https://mindmedicinelaw.com/briefing/colorado-s-ibogaine-law-and-its-impact-on-psilocybin-regulation-20260611-11993The Psychedelic Journalen2026-06-11T15:03:54.910697+00:00Colorado's Ibogaine Law and Its Impact on Psilocybin Regulationcolorado ibogaine law, psilocybin regulation, psychedelic substances, unlicensed sales, market dynamics, legal compliancehttps://mindmedicinelaw.com/briefing/breathwork-s-potential-in-inducing-altered-states-of-consciousness-20260610-12037The Psychedelic Journalen2026-06-11T22:05:34.522123+00:00Breathwork's Potential in Inducing Altered States of Consciousnessbreathwork, altered states of consciousness, psychedelics, therapeutic applications, non-pharmacological interventions, mental health, clinical trials, emotional breakthroughs, consciousness research, psychological insightshttps://mindmedicinelaw.com/briefing/molecular-features-in-lewy-body-dementia-cortical-atrophy-20260610-12070The Psychedelic Journalen2026-06-11T22:05:22.585307+00:00Molecular Features in Lewy Body Dementia Cortical Atrophylewy body dementia, cortical atrophy, molecular pathways, neurodegenerative research, clinical trials, GABAergic signaling, mitochondrial function, synaptic transmission, Parkinson's disease, Alzheimer's diseasehttps://mindmedicinelaw.com/briefing/machine-learning-enhances-autism-mouse-model-profiling-20260610-12071The Psychedelic Journalen2026-06-11T22:05:13.731133+00:00Machine Learning Enhances Autism Mouse Model Profilingmachine learning, autism spectrum disorder, behavioral profiling, genetic mouse models, psychedelic research, neurodevelopmental disorders, Shank3B knockout mice, phenotype detection, translational studies, therapeutic interventionshttps://mindmedicinelaw.com/briefing/patient-views-on-psychedelic-therapy-for-aud-insights-and-implications-20260610-12035The Psychedelic Journalen2026-06-11T22:04:58.061715+00:00Patient Views on Psychedelic Therapy for AUD: Insights and Implicationsalcohol use disorder, psychedelic therapy, patient perceptions, clinical trials, informed consent, treatment expectations, addiction treatment, ethical researchhttps://mindmedicinelaw.com/briefing/ethical-challenges-in-ketamine-therapy-in-norway-20260610-12082The Psychedelic Journalen2026-06-11T22:04:44.912073+00:00Ethical Challenges in Ketamine Therapy in Norwayketamine-assisted psychotherapy, ethical challenges, Norway, treatment-resistant depression, informed consent, therapeutic integrity, access to care, psychedelic therapies, principlist bioethics, health policyhttps://mindmedicinelaw.com/briefing/optimi-health-ships-psilocybin-to-uk-for-clinical-trials-20260610-11992The Psychedelic Journalen2026-06-11T15:04:04.628301+00:00Optimi Health Ships Psilocybin to UK for Clinical Trialsoptimi health, psilocybin shipment, clinical trials, international collaboration, psychedelic research, UK regulatory framework, therapeutic potential, cross-border supply, controlled substances, regulatory approvalshttps://mindmedicinelaw.com/briefing/epa-s-tsca-chemical-review-implications-for-psychedelics-20260610-11546The Psychedelic Journalen2026-06-10T22:04:18.636255+00:00EPA's TSCA Chemical Review: Implications for PsychedelicsEPA, TSCA, chemical review, psychedelic substances, regulatory compliance, market strategy, premanufacture notice, significant new use, microbial commercial activity, legal implicationshttps://mindmedicinelaw.com/briefing/nevada-expands-ketamine-program-in-mental-health-care-20260610-11838The Psychedelic Journalen2026-06-10T22:04:10.009051+00:00Nevada Expands Ketamine Program in Mental Health Careketamine program, interventional psychiatry, psychedelic-assisted therapy, mental health treatment, Nevada healthcare, clinical trials, psychedelic research, policy implications, patient access, treatment innovationhttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-export-to-uk-a-clinical-milestone-20260610-11837The Psychedelic Journalen2026-06-10T22:03:59.487627+00:00Optimi Health's Psilocybin Export to UK: A Clinical Milestonepsilocybin export, Optimi Health, UK Phase 2 trial, psychedelic research, international collaboration, regulatory frameworks, mental health treatments, clinical trials, therapeutic applications, market dynamicshttps://mindmedicinelaw.com/briefing/epa-s-snur-proposal-implications-for-psychedelic-research-20260610-11563The Psychedelic Journalen2026-06-10T15:06:41.610052+00:00EPA's SNUR Proposal: Implications for Psychedelic ResearchEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, manufacturing, processing, premanufacture notices, policy implicationshttps://mindmedicinelaw.com/briefing/psychedelics-and-adhd-systematic-review-highlights-research-gaps-20260610-11608The Psychedelic Journalen2026-06-10T15:06:30.332341+00:00Psychedelics and ADHD: Systematic Review Highlights Research Gapspsychedelics, ADHD treatment, systematic review, clinical trials, neuropsychiatric disorders, LSD, psilocybin, ketamine, serotonin receptors, psychedelic researchhttps://mindmedicinelaw.com/briefing/optimi-health-exports-psilocybin-for-uk-phase-2-trial-20260610-11686The Psychedelic Journalen2026-06-10T15:05:41.130938+00:00Optimi Health Exports Psilocybin for UK Phase 2 Trialpsilocybin export, Optimi Health, UK clinical trial, international collaboration, psychedelic research, regulatory framework, mental health treatment, Phase 2 trial, controlled substances, global healthcarehttps://mindmedicinelaw.com/briefing/gpcr-biased-signaling-new-frontiers-in-psychedelic-therapies-20260609-11609The Psychedelic Journalen2026-06-10T22:04:28.262478+00:00GPCR Biased Signaling: New Frontiers in Psychedelic TherapiesGPCR biased signaling, psychedelic therapies, drug development, clinical trials, serotonin receptor, mental health, pharmacology, regulatory frameworks, therapeutic innovation, signaling pathwayshttps://mindmedicinelaw.com/briefing/psychedelics-structure-activity-therapeutic-implications-20260608-12137The Psychedelic Journalen2026-06-11T22:05:05.400544+00:00Psychedelics: Structure-Activity & Therapeutic Implicationspsychedelic pharmacology, structure-activity relationships, neuropsychiatric disorders, clinical trial design, mental health treatment, psychedelic therapyhttps://mindmedicinelaw.com/briefing/n-acetylcysteine-in-ocd-treatment-promising-trial-results-20260608-11621The Psychedelic Journalen2026-06-10T15:06:05.307550+00:00N-acetylcysteine in OCD Treatment: Promising Trial Resultsn-acetylcysteine, obsessive-compulsive disorder, sertraline, clinical trial, adjunctive treatment, SSRI, glutamate modulation, Y-BOCS, placebo-controlled, cognitive functioninghttps://mindmedicinelaw.com/briefing/ketamine-vs-esketamine-depression-treatment-in-germany-20260608-11622The Psychedelic Journalen2026-06-10T15:05:53.086498+00:00Ketamine vs. Esketamine: Depression Treatment in Germanyketamine infusions, esketamine nasal spray, treatment-resistant depression, cost-effectiveness, German healthcare, clinical guidelines, psychedelic research, mental health policy, NMDA receptor, off-label usehttps://mindmedicinelaw.com/briefing/psychedelics-in-hospital-psychiatry-future-directions-20260604-11643The Psychedelic Journalen2026-06-10T22:04:38.079521+00:00Psychedelics in Hospital Psychiatry: Future Directionspsychedelic treatments, hospital psychiatry, clinical trials, neuroplasticity, policy considerations, psychiatric care, psilocybin, MDMA, patient safety, therapeutic outcomeshttps://mindmedicinelaw.com/briefing/ipa-s-depression-dementia-research-roadmap-future-directions-20260601-11582The Psychedelic Journalen2026-06-10T22:04:46.959250+00:00IPA's Depression-Dementia Research Roadmap: Future Directionsdepression, dementia, neurocognitive disorders, psychedelic therapies, biomarkers, precision psychiatry, caregiver burden, diagnostic criteria, multimodal interventions, brain healthhttps://mindmedicinelaw.com/briefing/ketamine-s-mechanisms-expand-beyond-nmda-antagonism-20260601-11684The Psychedelic Journalen2026-06-10T15:06:15.200768+00:00Ketamine's Mechanisms Expand Beyond NMDA Antagonismketamine, NMDA receptor, mental health treatment, neuroscience, clinical trials, psychedelic research, therapeutic potential, glutamate transmission, neurotransmitter systemshttps://mindmedicinelaw.com/briefing/psychedelics-influence-on-personality-updated-insights-20260531-11656The Psychedelic Journalen2026-06-11T15:04:13.161108+00:00Psychedelics' Influence on Personality: Updated Insightspsychedelics, personality traits, systematic review, therapeutic applications, individual variability, serotonin receptors, clinical trials